NASDAQ · ABSI
Absci Corporation
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
Loading market information…
NASDAQ · OFIX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Orthofix Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Orthofix Medical Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of $0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Orthofix Medical Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$1.35-255.26% vs estimate | $193.65M+1.34% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$0.75-2,600.0% vs estimate | $215.70M+1.4% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.07+146.67% vs estimate | $196.61M+0.04% vs estimate |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $13.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
$7.51-$0.30 (-3.84%)
Butterfly Network, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.44% below the high.
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$12.57+$0.26 (+2.11%)
MoonLake Immunotherapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.03% below the high.
$22.41+$0.58 (+2.66%)
SI-BONE, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.31% below the high.
$2.90+$0.07 (+2.47%)
Pacific Biosciences of California, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$18.44-$0.01 (-0.05%)
Varex Imaging Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$3.18$0.00 (0.0%)
Esperion Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.83% below the high.
